390 related articles for article (PubMed ID: 23186007)
1. From phage display to nanoparticle delivery: functionalizing liposomes with multivalent peptides improves targeting to a cancer biomarker.
Gray BP; Li S; Brown KC
Bioconjug Chem; 2013 Jan; 24(1):85-96. PubMed ID: 23186007
[TBL] [Abstract][Full Text] [Related]
2. A liposomal drug platform overrides peptide ligand targeting to a cancer biomarker, irrespective of ligand affinity or density.
Gray BP; McGuire MJ; Brown KC
PLoS One; 2013; 8(8):e72938. PubMed ID: 24009717
[TBL] [Abstract][Full Text] [Related]
3. A novel peptide probe for imaging and targeted delivery of liposomal doxorubicin to lung tumor.
He X; Na MH; Kim JS; Lee GY; Park JY; Hoffman AS; Nam JO; Han SE; Sim GY; Oh YK; Kim IS; Lee BH
Mol Pharm; 2011 Apr; 8(2):430-8. PubMed ID: 21222482
[TBL] [Abstract][Full Text] [Related]
4. Subtype-specific binding peptides enhance the therapeutic efficacy of nanomedicine in the treatment of ovarian cancer.
Shen YA; Liu CS; Chang YH; Chen PH; He CL; Wu HC; Chuang CM
Cancer Lett; 2015 Apr; 360(1):39-47. PubMed ID: 25661733
[TBL] [Abstract][Full Text] [Related]
5. Targeted delivery of anticancer drugs to tumor vessels by use of liposomes modified with a peptide identified by phage biopanning with human endothelial progenitor cells.
Fukuta T; Asai T; Kiyokawa Y; Nakada T; Bessyo-Hirashima K; Fukaya N; Hyodo K; Takase K; Kikuchi H; Oku N
Int J Pharm; 2017 May; 524(1-2):364-372. PubMed ID: 28359814
[TBL] [Abstract][Full Text] [Related]
6. Cell-specific delivery of a chemotherapeutic to lung cancer cells.
Zhou X; Chang YC; Oyama T; McGuire MJ; Brown KC
J Am Chem Soc; 2004 Dec; 126(48):15656-7. PubMed ID: 15571383
[TBL] [Abstract][Full Text] [Related]
7. Peptide-conjugated nanoparticles for targeted imaging and therapy of prostate cancer.
Yeh CY; Hsiao JK; Wang YP; Lan CH; Wu HC
Biomaterials; 2016 Aug; 99():1-15. PubMed ID: 27209258
[TBL] [Abstract][Full Text] [Related]
8. Landscape phage fusion protein-mediated targeting of nanomedicines enhances their prostate tumor cell association and cytotoxic efficiency.
Jayanna PK; Bedi D; Gillespie JW; DeInnocentes P; Wang T; Torchilin VP; Bird RC; Petrenko VA
Nanomedicine; 2010 Aug; 6(4):538-46. PubMed ID: 20138246
[TBL] [Abstract][Full Text] [Related]
9. Peptide-labeled supramolecular aggregates as selective doxorubicin carriers for delivery to tumor cells.
Morisco A; Accardo A; Tesauro D; Palumbo R; Benedetti E; Morelli G
Biopolymers; 2011; 96(1):88-96. PubMed ID: 20560147
[TBL] [Abstract][Full Text] [Related]
10. Accumulation, internalization and therapeutic efficacy of neuropilin-1-targeted liposomes.
Paoli EE; Ingham ES; Zhang H; Mahakian LM; Fite BZ; Gagnon MK; Tam S; Kheirolomoom A; Cardiff RD; Ferrara KW
J Control Release; 2014 Mar; 178():108-17. PubMed ID: 24434424
[TBL] [Abstract][Full Text] [Related]
11. A strategy for actualization of active targeting nanomedicine practically functioning in a living body.
Lee KJ; Shin SH; Lee JH; Ju EJ; Park YY; Hwang JJ; Suh YA; Hong SM; Jang SJ; Lee JS; Song SY; Jeong SY; Choi EK
Biomaterials; 2017 Oct; 141():136-148. PubMed ID: 28688285
[TBL] [Abstract][Full Text] [Related]
12. Tumor-targeted delivery of liposome-encapsulated doxorubicin by use of a peptide that selectively binds to irradiated tumors.
Lowery A; Onishko H; Hallahan DE; Han Z
J Control Release; 2011 Feb; 150(1):117-24. PubMed ID: 21075152
[TBL] [Abstract][Full Text] [Related]
13. Engineered peptides for the development of actively tumor targeted liposomal carriers of doxorubicin.
Shahin M; Soudy R; El-Sikhry H; Seubert JM; Kaur K; Lavasanifar A
Cancer Lett; 2013 Jul; 334(2):284-92. PubMed ID: 23073474
[TBL] [Abstract][Full Text] [Related]
14. Dual-receptor targeted strategy in nanoparticle design achieves tumor cell selectivity through cooperativity.
Stefanick JF; Omstead DT; Kiziltepe T; Bilgicer B
Nanoscale; 2019 Mar; 11(10):4414-4427. PubMed ID: 30801591
[TBL] [Abstract][Full Text] [Related]
15. From phage display to dendrimer display: insights into multivalent binding.
Bastings MM; Helms BA; van Baal I; Hackeng TM; Merkx M; Meijer EW
J Am Chem Soc; 2011 May; 133(17):6636-41. PubMed ID: 21473586
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and characterization of a high-affinity {alpha}v{beta}6-specific ligand for in vitro and in vivo applications.
Li S; McGuire MJ; Lin M; Liu YH; Oyama T; Sun X; Brown KC
Mol Cancer Ther; 2009 May; 8(5):1239-49. PubMed ID: 19435868
[TBL] [Abstract][Full Text] [Related]
17. Novel RGD lipopeptides for the targeting of liposomes to integrin-expressing endothelial and melanoma cells.
Hölig P; Bach M; Völkel T; Nahde T; Hoffmann S; Müller R; Kontermann RE
Protein Eng Des Sel; 2004 May; 17(5):433-41. PubMed ID: 15235124
[TBL] [Abstract][Full Text] [Related]
18. A novel peptide enhances therapeutic efficacy of liposomal anti-cancer drugs in mice models of human lung cancer.
Chang DK; Lin CT; Wu CH; Wu HC
PLoS One; 2009; 4(1):e4171. PubMed ID: 19137069
[TBL] [Abstract][Full Text] [Related]
19. Promiscuous tumor targeting phage proteins.
Gross AL; Gillespie JW; Petrenko VA
Protein Eng Des Sel; 2016 Mar; 29(3):93-103. PubMed ID: 26764410
[TBL] [Abstract][Full Text] [Related]
20. Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma.
Loi M; Marchiò S; Becherini P; Di Paolo D; Soster M; Curnis F; Brignole C; Pagnan G; Perri P; Caffa I; Longhi R; Nico B; Bussolino F; Gambini C; Ribatti D; Cilli M; Arap W; Pasqualini R; Allen TM; Corti A; Ponzoni M; Pastorino F
J Control Release; 2010 Jul; 145(1):66-73. PubMed ID: 20346382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
